Keywords: medarex, 3rd-qtr, loss, grows, charges, usa-based, biopharmaceutical
Medarex' 3rd-qtr loss grows 12% on charges
Article | 21 November 2007
USA-based biopharmaceutical firm Medarex says that its net loss for the three months ended September 30, 2007, was $51.6 million, or $0.41 per share, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
